Among 610 propensity-matched adults with comorbid epilepsy, type 2 diabetes, and obesity drawn from the NIH All of Us database, GLP-1 receptor agonist initiation produced a mean adjusted weight loss of 5.73% and an HbA1c reduction of 0.71% at 12 months — without increasing seizure-related hospitalizations or prompting new antiseizure medication additions (hazard ratio 0.92, 95% CI 0.68–1.23). Critically, even patients simultaneously taking weight-promoting antiseizure medications like valproate or pregabalin still achieved a meaningful 4.15% weight reduction.
This finding addresses a genuinely underserved clinical dilemma. Neurologists have long faced a therapeutic trap: valproate and pregabalin remain cornerstone seizure treatments yet reliably drive weight gain, compounding cardiometabolic risk in a population already prone to sedentary lifestyles and metabolic dysfunction. Prior reluctance to prescribe GLP-1 agonists in epilepsy stems partly from theoretical concerns — nausea-induced medication non-adherence and potential blood-glucose fluctuations affecting seizure threshold. This retrospective data provides meaningful, if not definitive, reassurance against that fear.
Limitations are real: the study is observational, cannot exclude residual confounding, and the power calculation reveals it could only detect hazard ratios above 1.53 — modest worsening could remain undetected. The database likely skews toward insured, health-system-engaged patients. Still, as GLP-1 agonists become first-line obesity tools, this is a timely, clinically actionable signal that epilepsy alone should not be a contraindication.